TherapeuticsMD, Inc. SEC filings TXMD
TherapeuticsMD, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 23, 2008. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Nov 3, 2025 | — |
| DEF 14A | Proxy statement | Nov 3, 2025 | Dec 15, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 24, 2025 | Oct 24, 2025 |
| DEFA14A | Additional proxy material | Oct 25, 2024 | — |
| DEF 14A | Proxy statement | Oct 25, 2024 | Dec 5, 2024 |
| DEFA14A | Additional proxy material | May 17, 2023 | — |
| DEF 14A | Proxy statement | May 17, 2023 | Jun 26, 2023 |
| PRE 14A | Preliminary proxy statement | May 1, 2023 | Jun 26, 2023 |
| DEFA14A | Additional proxy material | May 21, 2021 | — |
| DEFA14A | Additional proxy material | Apr 14, 2021 | — |
| DEF 14A | Proxy statement | Apr 14, 2021 | May 27, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2021 | May 27, 2021 |
| DEFA14A | Additional proxy material | May 4, 2020 | — |
| DEF 14A | Proxy statement | May 4, 2020 | Jun 18, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 20, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 25, 2018 |
| DEFA14A | Additional proxy material | Apr 25, 2017 | — |
| DEF 14A | Proxy statement | Apr 25, 2017 | Jun 16, 2017 |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 11, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2015 | Jun 11, 2015 |
| DEFA14A | Additional proxy material | Apr 17, 2014 | — |
| DEF 14A | Proxy statement | Apr 17, 2014 | Jun 5, 2014 |
| DEFA14A | Additional proxy material | Jul 12, 2013 | — |
| DEF 14A | Proxy statement | Jul 12, 2013 | Aug 22, 2013 |
| DEF 14C | Information statement | Sep 12, 2011 | Sep 12, 2011 |
| PRE 14C | Preliminary information statement | Jul 28, 2011 | Jul 28, 2011 |
| DEF 14C | Information statement | Jun 29, 2010 | Jul 20, 2010 |
| PRE 14C | Form pre 14c | May 7, 2010 | Jun 7, 2010 |
| DEF 14C | Information statement | Sep 4, 2009 | Sep 14, 2009 |
| PRE 14C | Preliminary information statement | Jul 30, 2009 | Aug 24, 2009 |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TXMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 25743
- Former names
- AMHN, Inc. (until Sep 14, 2011); CROFF ENTERPRISES INC (until Sep 4, 2009); CROFF OIL CO (until Apr 1, 1997)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.